Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. All News
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Real-time Estimate Cboe Europe  -  09:50 2022-12-05 am EST
49.58 CHF   +0.46%
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about BASILEA PHARMACEUTICA AG
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutic..
GL
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutic..
DJ
10/26Basilea Pharmaceutica : Updated October 26, 2022
PU
10/24Basilea to Submit New Drug Application for Bloodstream Infection Drug Ceftobiprole in 2..
MT
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
GL
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
AQ
10/24Basilea : ERADICATE phase 3 study results highlight the potential role of ceftob..
DJ
10/24Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Rol..
CI
10/13Basilea to Submit New Drug Application for Bacterial Bloodstream Infections Drug By 202..
MT
10/13Basilea announces late breaking presentation on the successfully completed ERADICATE ph..
GL
10/13Basilea announces late breaking presentation on the successfully completed ERADICATE ph..
AQ
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug
MT
09/21Basilea Pharmaceutica Secures $78 Million Senior Secured Loan From Athyrium Capital
MT
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
GL
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
DJ
09/20Basilea Pharmaceutica Boosts FY22 Revenue Outlook After Disposal Deal For Oncology Asse..
MT
09/20Basilea Pharmaceutica Sells Oncology Asset Rights To South Korea's SillaJen
MT
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
GL
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
DJ
09/20Basilea Pharmaceutica AG Revises Earnings Guidance for the Full Year 2022
CI
09/20Basilea Pharmaceutica AG Enters into Asset Purchase Agreement and Sub-License Agreement..
CI
09/08Basilea to Sell Preclinical Oncology Program to Nodus Oncology in $248 Million Deal
MT
09/08Basilea announces sale of preclinical oncology program to Nodus Oncology
GL
09/08Basilea announces sale of preclinical oncology program to Nodus Oncology
DJ
09/07Basilea Secures $76 Million Senior Secured Loan to Refinance Bonds Due December
MT
09/07Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-di..
GL
09/07Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-di..
DJ
09/07Basilea Pharmaceutica Enters into CHF 75 Million Senior Secured Loan Agreement with Fun..
CI
09/07Basilea Pharmaceutica AG announced that it has received CHF 75 million in funding from ..
CI
08/16Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022
CI
08/16Transcript : Basilea Pharmaceutica AG, H1 2022 Earnings Call, Aug 16, 2022
CI
08/16Basilea Pharmaceutica AG Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/16Basilea Pharmaceutica Narrows H1 Loss Amid Strong Growth Of Antifungal Cream
MT
08/16Basilea Pharmaceutica : Updated August 16, 2022
PU
08/16Basilea reports strong financial half-year results and progress in the implementation o..
GL
08/16Basilea reports strong financial half-year results and progress in the implementation o..
DJ
07/12Basilea Pharmaceutica JV Gains Brazilian Market Authorization For Pneumonia Treatment
MT
07/12Basilea announces Zevtera« (ceftobiprole) marketing authorization in Brazil
GL
07/12Basilea announces Zevtera« (ceftobiprole) marketing authorization in Brazil
AQ
07/12Basilea announces Zevtera(R) (ceftobiprole) marketing authorization in Brazil
DJ
06/28Transcript : Basilea Pharmaceutica AG - Special Call
CI
06/28Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Stap..
DJ
06/28Basilea Pharmaceutica Ltd. Positive Results of Phase 3 Eradicate Study with Ceftobiprol..
CI
06/27Basilea to Suspend Studies For Lisavanbulin, End Derazantinib Licensing Deal With Merck..
MT
06/27Basilea reports progress on the implementation of its strategy to focus on anti-infecti..
GL
06/27Basilea reports progress on the implementation of its strategy to focus on anti-infecti..
DJ
06/27Basilea Pharmaceutica AG Reports Progress on the Implementation of Its Strategy to Focu..
CI
06/24Switzerland's Basilea Wins Chinese Nod for New Formulation of Antifungal Drug
MT
06/24Basilea announces approval for additional formulation of antifungal Cresemba« (isavucon..
GL
06/24Basilea announces approval for additional formulation of antifungal Cresemba« (isavucon..
AQ
06/24Basilea announces approval for additional formulation of antifungal Cresemba(R) (isavuc..
DJ
06/17Pfizer to Pay $1.3 Million Milestone Payment to Basilea For Asia-Pacific Sales of Crese..
MT
06/17Cresemba« sales in Asia Pacific region trigger sales milestone payment to Basilea from ..
GL
06/17Cresemba« sales in Asia Pacific region trigger sales milestone payment to Basilea from ..
AQ
06/17Cresemba(R) sales in Asia Pacific region trigger sales milestone payment to Basilea fro..
DJ
05/24Transcript : Basilea Pharmaceutica AG Presents at UBS Global Healthcare Confe..
CI
04/27Basilea Pharmaceutica Licenses Antifungal Program From US-based Fox Chase
MT
04/27Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase..
AQ
04/27Basilea Pharmaceutica AG Announces Licensing of Novel First-In-Class Antifungal Program..
CI
04/13Basilea shareholders approve all proposals of the board of directors at the annual gene..
GL
04/13Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Boa..
CI
04/13Basilea's Oncology Drug Candidates Show Anti-Cancer Activity in Preclinical Trial
MT
04/13Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and ..
AQ
04/13Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891
CI
03/30Basilea Pharmaceutica : Updated March 30, 2022
PU
03/16Basilea Pharmaceutica : Shareholder letter EN
PU
03/08Basilea Pharmaceutica's BAL0891 Candidate Shows Anti-Cancer Activity in Preclinical Stu..
MT
03/08Basilea reports preclinical data on anti-cancer activity of novel oncology drug candida..
DJ
03/08Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candida..
CI
02/21Basilea Pharmaceutica : Updated Februaryá 21, 2022
PU
02/15Transcript : Basilea Pharmaceutica AG, 2021 Earnings Call, Feb 15, 2022
CI
02/15Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, ..
CI
1  2  3  4  5  6  7  8Next
Upcoming event on BASILEA PHARMACEUTICA AG